Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315000 | 0.97 | ALDH1A1 (0.38) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL18314942 | 0.89 | CYP2C9 (0.35) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL18314927 | 0.89 | ALDH1A1 (0.38) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL18315014 | 0.88 | CYP2C9 (0.35) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL18314929 | 0.88 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL18314932 | 0.87 | FASN (0.34) | — | |
| SCHEMBL18314930 | 0.87 | CYP2C9 (0.32) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL15460617 | 0.87 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL7732542 | 0.87 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL7732538 | 0.87 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | ALDH1A1 664/4885LMNA 3030/4885MAPT 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.